Research
Hormonal
The exaggerated postprandial secretion of GLP-1 and PYY following Roux-en-Y gastric bypass (RYGB) and Vertical Sleeve Gastrectomy (VSG) contributes to improved glucose tolerance and insulin sensitivity, although its necessity is debated.
Surgery increases beneficial gut hormones like GLP-1, which help regulate blood sugar and appetite. While this is a key part of why surgery works, it is not the only factor, and the body's response varies by procedure.
GoodQualifiesMEDIUM confidence
It is widely accepted that postprandial circulating GLP-1 levels are markedly elevated after RYGB, BPD, and VSG... The physiological relevance of increased GLP-1 secretion in mediating glycemic improvements after RYGB and VSG is contentiously debated.
Why this rating
Based on multiple human and animal studies, though results are mixed regarding its necessity.
Source
Mechanisms of Diabetes Improvement Following Bariatric/Metabolic Surgery
Rachel L. Batterham et al. · Diabetes Care · 2016
DOI 10.2337/dc16-0145
narrative_reviewCited 371×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Bariatric/metabolic surgery induces rapid type 2 diabetes remission through weight-independent mechanisms, primarily involving altered gut hormone secretion (GLP-1, PYY), bile acid metabolism, and intestinal glucose disposal, occurring before significant weight loss.Strong
- Bile acid metabolism and the gut microbiome are critical mediators of glycemic improvement after bariatric surgery, acting through FXR and TGR5 receptors to influence glucose production and utilization.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →